Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose-Finding, Phase II Study to Evaluate the Immunogenicity and Safety of the Bioreactor-generated EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 2 to 35 Months Old

NCT03268083 is registered in ClinicalTrials.gov with Enimmune Corporation as lead sponsor.

NCT NCT03268083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03268083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose-Finding, Phase II Study to Evaluate the Immunogenicity and Safety of the Bioreactor-generated EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 2 to 35 Months Old
Lead sponsor
Enimmune Corporation
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2016
Completion date
December 31, 2017
Enrollment
140 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

enterovirus infections